Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
about
The place of immunotherapy in the management of HCV-induced vasculitis: an updateHepatitis C Therapy in Renal Patients: Who, How, When?Immunological HCV-associated thrombocytopenia: short reviewClinical improvement induced by rituximab in two cases of type II mixed cryoglobulinaemia syndrome unresponsive to conventional treatments.Advances in the use of biologic agents for the treatment of systemic vasculitisPathogenesis, diagnosis and management of paraneoplastic glomerulonephritisHepatitis C and kidney disease: An overview and approach to management.A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.Rituximab-based treatment, HCV replication, and hepatic flares.Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report.Mixed cryoglobulinemia.Hepatitis C virus-induced cryoglobulinemia.New insights into HCV-related rheumatologic disorders: A review.An approach to the diagnosis and management of systemic vasculitis.Treatment in inflammatory neuropathies.Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature.Update on the role of rituximab in kidney diseases and transplant.Management of rheumatic disease with comorbid HBV or HCV infection.Antiviral therapy for HCV-associated cryoglobulinemic glomerulonephritis: case report and review of the literature.Experience with low-dose rituximab in off-label indications at two tertiary hospitals.Hepatitis C virus-induced vasculitis: therapeutic options.Extrahepatic manifestations in chronic hepatitis C virus carriers.Diagnosis and therapeutic options for peripheral vasculitic neuropathy.Treatment of hepatitis C-related kidney disease.Extrahepatic manifestations of HCV: the role of direct acting antivirals.Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease.Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infectionSafety and efficacy of rituximab treatment for vasculitis in hepatitis B virus-associated type II cryoglobulinemia: a case report.Therapeutic antibodies and infectious diseases, Tours, France, November 20-22, 2012.Mortality rate and outcome factors in mixed cryoglobulinaemia: the impact of hepatitis C virus.A retrospective analysis of treatment outcomes in patients with hepatitis C related systemic vasculitis receiving intravenous methylprednisolone and cyclophosphamide.Pulmonary-renal syndrome in hepatitis C infection and rheumatoid arthritis.Hepatitis C and autoimmunity: a therapeutic challenge.Essential mixed cryoglobulinemia type III with leukocytoclastic vasculitis: remission by rituximab.
P2860
Q27015124-775B046D-22DF-4E45-A5F1-1D9C8EDFDB9BQ28077130-DDFFD3BD-C23E-4F29-83D4-E3A86F4DB0A2Q33402517-1407C07A-0CE2-4A6B-AD43-FB2012F4D0E6Q34003524-1E3B60E3-204D-40FA-8DCD-6132F2FD468FQ34065598-63C5039D-857D-4370-91E0-1C2C958077F8Q34684475-64E8CE64-25D9-445D-BA17-BA2F8D0E184CQ34966853-62F31314-2991-42C6-81CB-389EFB151125Q35624871-9402417F-DFC4-4019-902E-8CA9B7BED9B4Q36167378-8BC5C30A-FCBB-4265-8E49-E11146BE4103Q36327187-F96523F3-597A-4B11-A760-1002B34F6BBDQ36942539-C45DFF68-5279-4ADA-A737-D7927160C855Q37371397-CFFB8C24-6E4B-421A-AFEA-B7FD08A75E8CQ37610871-D2250449-710B-46A3-A869-5F9654F3B23CQ37673239-66846F84-E87A-4245-A5BE-773A76B70E4EQ37733512-C58CBB3C-B124-4130-AC6E-C31B1B75C082Q37807326-AE8B44DE-70FE-4DEA-8D73-40BE91AA65FCQ37970443-3D876608-8CE1-457B-9224-20FCA7F01991Q38008173-977B6F42-9510-499E-B8B6-3B271A5568BEQ38073147-54622484-16FD-4230-A49C-F2D461DAF1C6Q38126924-B4EBA707-BD23-42FA-93F0-45D1C5411C96Q38127143-6AF468E9-6C91-4733-953A-E45316EFD3EBQ38388423-ED9E9B14-9D30-44BD-802D-0187F2C16290Q38398833-395C8985-E0A1-4A8F-B173-F69770F760BCQ38544801-B993DB48-55B7-4363-8CB8-C4934B0EF079Q38684508-8916BD4F-CBC4-453F-9C70-E8C7422A085FQ39455853-59680B65-375A-4D75-A967-262D5BAA55EEQ40528517-106C3604-12FD-49F8-8EF9-97A01468AA01Q41806895-3EDB0315-778C-491C-B02C-11726AAAEFB9Q42609593-FAC19478-93A7-440B-AE62-4AD4BE8E9247Q42846265-F5C15F2F-C546-403F-9EED-BEEB9F8C59C4Q42995784-C21A5A39-BC79-4EB5-B081-4EF326F91CC6Q43000401-49B874DA-85C4-4846-97E7-12D305EB2FD5Q43013071-1D8CB3D1-8D16-4027-87D1-7A160DE3BBD9Q50556438-98A7A9E7-32F8-443D-892A-32D82773EE94Q51578806-D5FB97EA-3DE7-46C1-9B73-BC4809BBD1CF
P2860
Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Anti-CD20 monoclonal antibody ...... vasculitis: where do we stand?
@en
type
label
Anti-CD20 monoclonal antibody ...... vasculitis: where do we stand?
@en
prefLabel
Anti-CD20 monoclonal antibody ...... vasculitis: where do we stand?
@en
P2093
P356
P1476
Anti-CD20 monoclonal antibody ...... vasculitis: where do we stand?
@en
P2093
P304
P356
10.1136/ARD.2006.065565
P407
P577
2007-07-20T00:00:00Z